Supplement Figure: P1-0 P2-0 P1-1 P2-1 P1-3 P2-3

Supplement Figure:

P1-0 P2-0

P1-1 P2-1

P1-3 P2-3

Supplement Figure 1 Frequencies of specific TRBV and TRBJ gene pairing of total TCR-β CDR3

sequences at three time-points of P1 and P2 treated with high dose glucocorticoid therapy.

P1-0

P1-1

P1-3

P2-0

P2-1

P2-3

Supplement Figure 2 Frequencies of specific TRBV and TRBJ gene pairing of unique TCR-β CDR3

sequences at three time-points of P1 and P2 treated with high dose glucocorticoid therapy

Supplement Table 1 The top fifteen overlap TCR-β CDR3 AA sequences between in P1-0 and P2-0

P1-0 & P2-0

overlap CDR3 In P1-0

% In

P2-0

P1-0 & P2-0 overlap CDR3

In P2-0 % In P1-0

ASSQVSGDEQY 179 0.024473579 74 ASSLTGYEQY 233 0.023433029 31 ASSLEGYEQY 139 0.019004623 108 ASSTSGRAGEQF 204 0.020516472 4 ASSLGYEQY 125 0.017090488 47 ASSLGQSYEQY 204 0.020516472 21 ASRDRSYEQY 106 0.014492734 62 ASSLDSSYEQY 195 0.019611334 26 ASSLSSYEQY 91 0.012441875 155 ASSGYEQY 161 0.016191922 29 ASSLGGYEQY 81 0.011074636 41 ASSLSSYEQY 155 0.015588496 91 ASSLGGSYEQY 75 0.010254293 40 ASSPRGSYEQY 152 0.015286783 9 ASSLNYEQY 74 0.010117569 57 ASSSSYEQY 141 0.014180503 21 ASSSGTYEQY 61 0.008340158 17 ASSPTSGSYEQY 118 0.011867371 26 ASSLGTSSYEQY 53 0.007246367 50 ASSLRYEQY 116 0.011666229 12 ASSLVYEQY 47 0.006426023 46 ASGNYEQY 116 0.011666229 10 ASSLRDRGYEQY 45 0.006152576 41 ASSSQGYEQY 115 0.011565658 11 ASSLAGNEQF 43 0.005879128 46 ASSLGTGSYEQY 115 0.011565658 36 ASSLGNEQF 43 0.005879128 11 ASSLVGEQY 113 0.011364516 18 ASSLEGSYEQY 41 0.00560568 25 ASSRTSGSNEQY 113 0.011364516 17

Supplement Table 2 The top fifteen overlap TCR-β CDR3 AA sequences between in P1-1 and P2-1

P1-1 & P2-1

overlap CDDR3 In P1-1

% In P2-1 P1-1 & P2-1 overlap CDDR3

In P2-1 % In

P1-1 ASSPGQGYEQY 157 0.01237734 3 ASSSLSSYEQY 598 0.090521574 22 ASSPGPSYEQY 125 0.00985457 26 ASSLTGYEQY 168 0.02543081 48 ASSLGYEQY 94 0.007410637 3 ASSLRDEQF 156 0.023614324 8 ASSLVYEQY 93 0.0073318 9 ASSLGGAYEQY 122 0.018467612 40 ASSSYEQY 89 0.007016454 54 ASSQGYEQY 111 0.016802499 51 ASSLGQGSYEQY 86 0.006779944 4 ASSLAGGPYEQY 84 0.012715405 52 ASSTGTGGYEQY 83 0.006543435 2 ASSSSYEQY 80 0.01210991 54 ASRDRGSYEQY 83 0.006543435 19 ASSRTSGSYNEQF 77 0.011655788 29 ASSLGQGYEQY 78 0.006149252 23 ASSPTSGSSYNEQF 71 0.010747545 13 ASSPGQGAYEQY 75 0.005912742 31 ASSLQGYEQY 68 0.010293423 71 ASSQEGYEQY 74 0.005833906 40 ASSLYNEQF 68 0.010293423 20 ASSLQGYEQY 71 0.005597396 68 ASSPQGTYEQY 67 0.010142049 27 ASSLGDEQY 69 0.005439723 9 ASSLGPSYEQY 64 0.009687928 44 ASSQGTSGLYEQY 68 0.005360886 23 ASSLGTGGYEQY 63 0.009536554 19 ASSLGGTYEQY 67 0.00528205 38 ASSPGQSYEQY 59 0.008931058 10

Supplement Table 3 The top fifteen overlap TCR-β CDR3 AA sequences between in P1-3 and P2-3

P1-3 & P2-3

overlap CDDR3 In P1-3

% In

P2-3

P1-3 & P2-3 overlap CDDR3

In P2-3

% In

P1-3 ASSSGSYEQY 472 0.034417835 14 ASSPGDEQF 2037 0.25629605 22 ASRDRSYEQY 234 0.017063079 30 ASSLTYYEQY 273 0.034348955 32 ASSLSSYEQY 221 0.016115131 50 ASSLSYEQY 165 0.020760358 72 ASSLGYEQY 215 0.015677616 117 ASSLGYEQY 117 0.014720981 215 ASSLGGYEQY 215 0.015677616 75 ASSYSYEQY 105 0.013211137 107 ASSLGGGSSYEQY 207 0.015094263 70 ASSLGPNEQF 104 0.013085316 11 ASRGSYEQY 205 0.014948424 36 ASSGGYEQY 102 0.012833676 36 ASSLAYEQY 186 0.013562961 50 ASSPGTGSYEQY 90 0.011323831 21 ASSLAGSSYEQY 184 0.013417122 21 ASSLGNEQF 82 0.010317269 31 ASSPGLAGVYEQY 167 0.012177497 33 ASSLAGGYEQY 80 0.010065628 42 ASSLGREQY 167 0.012177497 42 ASSLGGYEQY 75 0.009436526 215 ASSGQGDEQY 165 0.012031659 41 ASSSSYEQY 73 0.009184885 35 ASSLVSIYEQY 158 0.011521225 14 ASSLGGGSSYEQY 70 0.008807424 207 ASSPRDRGYEQY 150 0.010937871 33 ASSLGGGEQY 63 0.007926682 52

   

Supplement Table 4 Leukocyte and lymphocyte counts of P1 and P2 at three monitoring moments before and after treatment

Patient Before treatment 1 month after treatment 3 months after treatment P1

P2

7.30

^a

/2.92

^b

7.02/2.81

4.70/1.88 3.60/1.44

7.1/2.84 7.9/3.16

Note. a=the number of leukocyte b=the number of lymphocytes

Supplement Table 5 Antinuclear antibody levels of P1 and P2 at three monitoring moments before and after treatment

P1 P2 Antinuclear antibodies

P1-0 P1-1 P1-3 P2-0 P2-1 P2-3

Anti-nRNP/SM +++ ++ ++ +++ ++ +

Anti-SM

- - -

++ + -

Anti-SSA +++ +++ +++ +++ +++ +++

Anti-RO-52 - - - +++ +++ +++

Anti-SSB - - - + - -

Anti-SCOL-70 - - - - - -

Anti-JO-1 - - - - - -

Anti-CENP B - - - - - -

Anti- dsDNA +++ ++ ++ + - -

Anti- nucleosome Anti- histone Anti- ribosomal P ACA

+++ +++ +++

+++ + + - - - - - -

- - - - - - +++ +++ ++

- - -

C3 0.36 0.55 0.42 0.3 0.46 0.81